Back to User profile » Dr Thomas Grint
Paper published by Dr Thomas Grint:
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray
Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S
Therapeutics and Clinical Risk Management 2016, 12:1667-1675
Published Date: 11 November 2016